跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
FGFR+VEGFR
首页
药物
FGFR+VEGFR
FGFR+VEGFR
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
Azaindole kinase inhibitors
US 6969717 B2
申请人: BRISTOL MYERS SQUIBB CO
优先权: 2002
CN
US
12 件公开
METHOD FOR TREATMENT OF TUMOR BY USING RECOMBINANT ONCOLYTIC VIRUS IN COMBINATION WITH SMALL-MOLECULE ANTICANCER DRUG
US 20260021149 A1
申请人: JOINT BIOSCIENCES SH LTD
优先权: 2023
CN
EP
US
WO
7 件公开
COMBINATION OF A PD-1 ANTAGONIST, A VEGFR/FGFR/RET TYROSINE KINASE INHIBITOR AND A CBP/BETA-CATENIN INHIBITOR FOR TREATING CANCER
EP 4051278 A1
申请人: EISAI R&D MAN CO LTD
优先权: 2019
CN
EP
US
WO
5 件公开
Process for the preparation of a sulfonamide structured kinase inhibitor
US 10870637 B2
申请人: ORION CORP
优先权: 2017
CN
EP
US
5 件公开
Pyrrolotriazine inhibitors of kinases
US 6982265 B1
申请人: BRISTOL MYERS SQUIBB CO
优先权: 2000
US
5 件公开
COMBINATION OF ANTIBODY-DRUG CONJUGATE AND KINASE INHIBITOR
US 2022040324 A1
申请人: DAIICHI SANKYO CO LTD
优先权: 2018
CN
EP
US
WO
4 件公开
Heterocyclic inhibitors of kinases
US 7084160 B2
申请人: BRISTOL MYERS SQUIBB CO
优先权: 2003
US
4 件公开
COMPLEMENT ANTIBODY-DRUG CONJUGATES
EP 4719387 A2
申请人: ADS THERAPEUTICS LLC
优先权: 2023
CN
EP
WO
3 件公开
Salt form and crystal form serving as FGFR and VEGFR inhibitor compounds, and preparation method therefor
US 11078194 B2
申请人: HARBIN ZHENBAO PHARMACEUTICAL CO LTD
优先权: 2017
CN
US
3 件公开
Method for treating diseases associated with abnormal kinase activity
US 6998391 B2
申请人: SUPERGEN INC
优先权: 2002
US
3 件公开
第 1 / 4 页
上一页
下一页
药物
反馈